Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Neoplasms 3Lung Neoplasms 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available 1Non-Small Cell Lung Cancer Metastatic 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Deafness, Autosomal Recessive 39 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 71apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × tepotinib × Clear all
NCT05439993 2022-07-05

Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

Hallym University Medical Center

Phase 1/2 Recruiting
42 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡